학술논문

The difference between concealment and blinding in clinical trials and why both are important. A reply to Garg and Mickenautsch, BMC Medical Research Methodology (2022) 22:17.
Document Type
Article
Source
BMC Medical Research Methodology. 11/21/2023, Vol. 23 Issue 1, p1-3. 3p.
Subject
*ISCHEMIC stroke
*CLINICAL trials
*MEDICAL research
*RESEARCH methodology
*THROMBOLYTIC therapy
Language
ISSN
1471-2288
Abstract
The letter responds to a paper that claims there was a risk of selection bias in the NINDS rt-PA for Acute Ischemic Stroke Study. The authors of the letter argue that the paper contains factual errors and misconceptions about the study. They clarify that there were errors in the randomization process, but these errors did not contribute to bias in the treatment effect. The authors also explain the difference between concealment and blinding in clinical trials and refute the suggestion that treatment assignment was manipulated. They emphasize the benefits of thrombolytic therapy for acute ischemic stroke and urge readers to review the literature on the topic. [Extracted from the article]